Healthcare Technology Report January 25, 2024

The U.S. Food and Drug Administration (FDA) has granted approval for Medtronic’s Percept RC deep brain stimulation (DBS) system, marking a significant advancement in the treatment of Parkinson’s disease and other movement disorders. DBS is a surgical procedure involving the implantation of an electrode in the brain to deliver electrical stimulation to specific regions, offering relief from debilitating symptoms.

Medtronic’s Percept RC system is recognized as the smallest and thinnest dual-channel neurostimulator designed for DBS. This newly approved technology incorporates BrainSense, an exclusive feature enabling the monitoring of brain activity. The system’s compact design and innovative capabilities aim to enhance the precision and personalization of DBS therapy.

Amaza Reitmeier, Vice President and General Manager of Brain Modulation at Medtronic, expressed...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: FDA, Govt Agencies, Medical Devices, Patient / Consumer, Provider
Related Articles:
FDA Approves First Biosimilar of Xolair
Opinion: STAT+: How will the Center for Biologics Evaluation and Research change under RFK Jr.?
How the FDA Opens the Door to Risky Chemicals in America’s Food Supply
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

Share This Article